Supplementary Table 3. Baseline characteristics of participants who were lost to follow-up and those who completed follow-up

Variables	Total (N=39)	Loss to follow-up (N=24)	Completed follow-up (N=15)	p†
Age (year)	42.10±5.59	42.88±5.34	40.87±5.94	0.131
BMI (kg/m^2)				
≥23	18 (46.2)	10 (41.7)	8 (53.3)	0.477
Marital status				>0.999
Single/divorced/widowed	8 (20.5)	5 (20.8)	3 (20.0)	
Married	31 (79.5)	19 (79.2)	12 (80.0)	
Occupation status				>0.999
Employed/self-employed	13 (33.3)	8 (33.3)	5 (33.3)	
Homemaker/unemployed/on leave/retired	26 (66.7)	16 (66.7)	10 (66.7)	
Household income (USD/month)				0.129
<3,600	19 (48.7)	14 (58.3)	5 (33.3)	
≥3,600	20 (51.3)	10 (41.7)	10 (66.7)	
Education				0.022*
Up to high school	22 (56.4)	17 (70.8)	5 (33.3)	
College graduate or higher	17 (43.6)	7 (29.2)	10 (66.7)	
Religion				0.571
Yes	23 (59.0)	15 (62.5)	8 (53.3)	
No	16 (41.0)	9 (37.5)	7 (46.7)	
Current smoker	1 (2.6)	0 (0.0)	1 (6.7)	0.385
Receptor status				
ER positive	30 (76.9)	16 (66.7)	14 (93.3)	0.115
PR positive	29 (74.4)	16 (66.7)	13 (86.7)	0.263
HER2 positive	25 (64.1)	16 (66.7)	9 (60.0)	
Disease stage				0.499
I	4 (10.3)	2 (8.3)	2 (13.3)	
II	26 (66.7)	15 (62.5)	11 (73.3)	
III	9 (23.1)	7 (29.2)	2 (13.3)	
Type of chemotherapy				0.020*
Adjuvant	25 (64.1)	12 (50.0)	13 (86.7)	
Neo-adjuvant	14 (35.9)	12 (50.0)	2 (13.3)	
Chemotherapy regimen				0.352
AC → D‡	24 (61.5)	12 (50.0)	12 (80.0)	
Weekly PCb → AC	4 (10.3)	4 (16.7)	0 (0.0)	
TC	4 (10.3)	3 (12.5)	1 (6.7)	
AC	2 (5.1)	1 (4.2)	1 (6.7)	
Pembrolizumab+Cb+D → Pembrolizumab+AC	2 (5.1)	2 (8.3)	0 (0.0)	
Others§	3 (7.7)	2 (8.3)	1 (6.7)	
Cumulative dose (mg/m^2)‖				
Doxorubicin	225.78±53.43	238.88±3.49	212.68±75.06	0.436
Cyclophosphamide	2378.20±53.78	2391.88±32.18	2361.78±70.25	0.235
Docetaxel	299.58±6.52	301.01±3.64	297.79±8.91	0.311
HADS				
Anxious	4 (10.3)	2 (8.3)	2 (13.3)	0.631
Depressed	11 (28.2)	6 (25.0)	5 (33.3)	0.718
PSQI				
Poor sleep quality	26 (66.7)	17 (70.8)	9 (60.0)	0.485
MSPSS				
High total PSS	32 (82.1)	20 (83.3)	12 (80.0)	>0.999
High PSS from significant others	24 (61.5)	14 (58.3)	10 (66.7)	0.603
High PSS from family	31 (79.5)	19 (79.2)	12 (80.0)	>0.999
High PSS from friends	27 (69.2)	16 (66.7)	11 (73.3)	0.734

Data are presented as mean±SD or number (%). *p<0.05; †chi-square test, Fisher's exact test (marital status, current smoker, ER and PR positivity, HADS, MSPSS total and friends), student t-test (cyclophosphamide and docetaxel), Mann–Whitney U test (age and doxorubicin); ‡doxorubicin 60 mg/m^2 and cyclophosphamide 600 mg/m^2 once every 3 weeks for four cycles, followed by docetaxel 300 mg/m^2 once every 3 weeks for four cycles; §two participant from the "loss to follow-up" group received TCHF (docetaxel+carboplatin+trastuzumab+pertuzumab) and CMF (cyclophoasphamide+methotrexate+5-fluorouracil), and one participants from the "completed follow-up" group received TCyH (docetaxel+cyclophosphamide+trastuzumab); ‖dose for doxorubicin, cyclophsophamide, and docetaxel were available for 20, 22, and 18 participants, respectively. BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AC, doxorubicin/cyclophosphamide; D, docetaxel; PCb, paclitaxel/carboplatin; TC, docetaxel/cyclophosphamide; HADS, hospital anxiety and depression scale; PSQI, Pittsburg sleep quality index; MSSPSS, Multidimensional Scale of Perceived Social Support; PSS, perceived social support; SD, standard deviation